Camlin Fine Sciences Ltd

- Currently, Camlin Fine Sciences Limited does not have any large CAPEX plans, which suggests limited immediate need for fundraising. - The company’s net debt is around Rs. 565 crores as of September 30, 2023, with long-term debt of about Rs. 230 crores repayable over 5 to 7 years. - Management indicated uncertainty regarding becoming debt-free, mentioning it could take 2 to 4 years depending on market conditions. - They are keeping multiple alternatives in mind due to volatile market conditions but have not disclosed any specific plans for raising new debt or equity in the near term.

- No large CAPEX is currently planned for the near term. - Net debt stands at about Rs. 565 crores, with Rs. 230 crores as long-term debt repayable over 5-7 years. - Vanillin project CAPEX incurred is Rs. 290 crores; future payback period now estimated at 4-5 years due to market conditions. - For the NegoLyte factory (750 tons capacity), CAPEX is being done by Lockheed Martin. - Larger scale Vanillin plant CAPEX and investment responsibility are under ongoing discussions. - The company is monitoring market conditions before deciding on future investment strategies.

- Blends business is expected to grow strongly at 25%-30% annually, driven by stabilized operations and market expansion in North America, Brazil, Mexico, Europe, and Africa. - Vanillin business aims to achieve about 90% capacity utilization by FY26, with revenue expected to ramp up over the next 2 years, reaching around Rs. 700-800 crores eventually. - Current year focuses on liquidating inventory and starting supplies from awarded contracts from January onwards, with business momentum expected to build from Q4. - Performance chemicals segment anticipated to recover gradually, especially with improvements in the Italian subsidiary’s operations, potentially increasing its revenue contribution. - Growth in aroma segment expected post product validation and contracting phase, with ramp-up expected from Q4 onwards. - Overall, a cautious but positive outlook with target market share increase and meaningful progress anticipated by FY26.

- Blends business expected to grow at 25%-30% annually, driven by robust demand across geographies including Vietnam, Thailand, Europe, and Africa. - Performance chemicals segment growth depends on the turnaround of Italian subsidiary and new downstream products like hydroquinone and catechol. - Vanillin business aims to ramp up to 90% capacity in two years, targeting gross margins of 15%-25%; payback period for Vanillin project now estimated at 4-5 years due to market conditions. - Margin pressure may persist short term if crude oil prices spike sharply; raw material costs have stabilized recently. - Market uncertainties and geopolitical factors may impact near-term performance, but Q4 and second half expected to show improvement. - Debt expected to be managed carefully; no large CAPEX planned, with focus on maintaining financial stability. - Overall, longer-term growth prospects remain positive with incremental contributions from aroma and performance chemicals alongside blends.

- Camlin Fine Sciences has bid for Vanillin contracts totaling over 4,000 tons. - Supplies for awarded contracts are expected to begin from January (next financial year). - They are hopeful to secure a substantial portion of these bids within 30 to 45 days after the call. - Current Vanillin inventory is valued around Rs. 50 crores, with an additional Rs. 20 crores in Ethyl Vanillin inventory being built. - The company expects to liquidate existing Vanillin stock and grow sales through new contracts. - Fixed-price contracts are typically for one year duration with limited pricing volatility unless price changes exceed predefined bands. - No specific broad order book value was disclosed, but bidding activity indicates an improving order flow starting next quarter.